Welcome to our dedicated page for Biolargo news (Ticker: BLGO), a resource for investors and traders seeking the latest updates and insights on Biolargo stock.
Biolargo, Inc. (BLGO) delivers innovative cleantech solutions for critical environmental challenges, from advanced water treatment to sustainable energy storage. This news hub provides investors and industry professionals with timely updates on the company’s progress in commercializing its technologies.
Discover official press releases, financial announcements, and operational milestones related to BLGO’s core initiatives: PFAS remediation systems, water treatment innovations, Cellinity energy storage technology, and strategic partnerships. The page serves as a neutral, factual resource for tracking the company’s execution of its environmental technology roadmap.
Key updates include regulatory developments, patent approvals, partnership agreements, and product commercialization efforts. All content is curated to meet investor needs for decision-ready information while adhering to financial disclosure standards.
Bookmark this page or check back regularly for verified updates directly from Biolargo and trusted financial news sources. For historical context, explore archived announcements demonstrating the company’s evolving cleantech portfolio.
BioLargo (OTCQX:BLGO), a cleantech and environmental solutions company, reported its Q2 2025 financial results with revenues of $2.77 million for Q2 and $6.04 million for H1 2025. The company highlighted significant progress across multiple divisions, with its engineering segment experiencing a 517% revenue increase in air quality control services.
Notable achievements include Clyra Medical Technologies securing distribution agreements covering 6,100 hospitals and thousands of medical facilities, while the company's Cellinity battery technology received validation from U.S. BESS Corporation and secured four MOUs for potential factory partnerships. As of June 30, 2025, BioLargo maintained a strong financial position with $3.47 million in cash, total assets of $12.49 million, and stockholders' equity of $6.06 million.
BioLargo (OTCQX:BLGO), a sustainable technology developer and environmental engineering company, will host a Q2 2025 earnings webcast and conference call on Friday, August 15th, 2025, at 11:00 AM ET.
The event will review financial results for the quarter ending June 30th, 2025, discuss recent milestones, and include a Q&A session. Participants can join via webcast or teleconference, with replay available until August 29th, 2026. Registration should be completed 15 minutes before the scheduled start time.
BioLargo (OTCQX:BLGO) provided a comprehensive mid-year review for 2025, highlighting significant progress across its subsidiaries. The company's 52%-owned Clyra Medical secured distribution agreements covering 6,100 hospitals and received a $3.3 million capital infusion. Their revolutionary Cellinity battery technology has attracted four MOUs for potential joint ventures, with each planned factory capable of generating $500 million in annual revenue. The company's PFAS water treatment technology is advancing with its first paid project in New Jersey and successful pilot programs for Fortune 500 clients. However, BioLargo faced challenges in its ONM Environmental division, experiencing decreased revenue and increased accounts receivable due to declining sales of private-labeled pet-odor control products.
BioLargo (OTCQX:BLGO) has initiated alpha testing of Verralize's portable PFAS water test kit at its Oak Ridge, Tennessee laboratory. The innovative "lab-on-a-sensor" kit enables rapid, on-site detection of PFAS (per- and polyfluoroalkyl substances), commonly known as "forever chemicals" regulated under the U.S. Safe Drinking Water Act.
The test kit's key features include user-friendly operation, low cost, and the ability to distinguish between different PFAS molecules. Testing will be conducted using contaminated water from BioLargo's existing and scheduled pilot projects. Upon successful validation, BioLargo plans to integrate the kit into its PFAS treatment services and distribute it through its nationwide network of manufacturer's sales representatives.
The company will showcase its PFAS solutions and the Verralize test kits at WEFTEC 2025 this September. This strategic initiative aims to enhance BioLargo's PFAS treatment systems and provide clients with real-time contamination monitoring capabilities.
BioLargo (OTCQX:BLGO), an environmental and cleantech solutions company, announced the approval of all matters at its 2025 annual stockholder meeting. While shareholders approved a potential 10-for-1 reverse stock split, management clarified they have no immediate plans to implement it.
CEO Dennis Calvert emphasized that the company would only consider the reverse split if needed to meet minimum price requirements for uplisting to Nasdaq or NYSE. BioLargo currently meets all uplisting qualifications except for stock price, and management views this approval as strategic preparation for potential future opportunities.
BioLargo (OTCQX:BLGO), a company focused on sustainable environmental and health technologies, has scheduled its Q1 2025 earnings conference call and webcast for Thursday, May 15, 2025, at 4:30 PM Eastern Time. The event will cover financial results for the quarter ending March 31, 2025, recent company milestones, and include a Q&A session.
Participants can join via webcast or teleconference, with domestic and international dial-in numbers provided. The webcast replay will be available until August 15, 2025, while the teleconference replay will be accessible until May 29, 2025. All presentation materials will be posted on BioLargo's investor relations website.
BioLargo (OTCQX:BLGO) announced that its subsidiary Clyra Medical Technologies has secured multiple distribution agreements for its medical products in domestic and international markets. While these agreements don't include minimum purchase requirements, they each have the potential to generate significant revenue for Clyra. CEO Dennis P. Calvert highlighted the company's investment in meeting client specifications and bringing products to market, though no specific timeline or sales volume predictions were provided.
BioLargo (OTCQX:BLGO) has revealed case study data demonstrating that its AEC (Aqueous Electrostatic Concentrator) PFAS solution can achieve over 80% lifecycle cost savings compared to traditional carbon-based treatment systems. The technology effectively captures and destroys PFAS contamination to non-detect levels in drinking water, wastewater, and landfill leachate.
The significant cost reduction is attributed to the AEC's ability to generate less PFAS-laden waste compared to conventional methods like granular activated carbon (GAC) and ion exchange resins, coupled with lower replacement costs for treatment materials. Unlike traditional methods, the AEC doesn't suffer from breakthrough or channeling phenomena, particularly with short chain PFAS, leading to reduced maintenance frequency and better PFAS capture efficiency.
BioLargo (OTCQX: BLGO), a cleantech and environmental solutions company, has announced its participation in the upcoming 15th Annual LD Micro Invitational at the Westin Grand Central in New York. The company's President & CEO Dennis P. Calvert will deliver a presentation on April 10, 2025, at 2:30 PM Eastern Time, covering the company's financial performance from the previous year and current business initiatives.
The LD Micro Invitational XV is scheduled for April 9-10, 2025, featuring over 50 presenting companies. The event will commence with registration at 2:00 PM ET on April 9th, followed by keynote speeches. Companies will present in 30-minute segments and participate in private investor meetings throughout the two-day conference.